ChemicalBook Product Catalog Biochemical Engineering Nucleoside drugs Nucleotides and their analogs 5-Azacytidine

1/1

5-Azacytidine

$2.00 100kg

$4.00 10kg

$5.00 1kg

Min. Order1kg
Purity99%
Cas No320-67-2
Supply Ability100kg
Update time2025-10-13

ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD

VIP1Y

China

Chemical Properties

Product Name	5-Azacytidine
CAS No	320-67-2
EC-No
Min. Order	1kg
Purity	99%
Supply Ability	100kg
Release date	2025/10/13

PRODUCT INFORMATION

Name	5-azacytidine
Synonym	More Synonyms

Description	5-Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Epigenetics >> DNA Methyltransferase Signaling Pathways >> Cell Cycle/DNA Damage >> Nucleoside Antimetabolite/Analog Research Areas >> Cancer
Target	DNMT1 Nucleoside Antimetabolite/Analog Autophagy
In Vitro	Unmethylated CpG islands associated with a variety of genes become partially or fully methylated in tumors and can be reactivated by 5-Azacytidine[1]. 5-Azacytidine acts as weak inducers of erythroid differentiation of Friend erythroleukemia cells in the same concentration range where they affect DNA methyltransferase activity[2]. 5-Azacytidine inhibits L1210 cells with ID50 and ID90 values of 0.019 and circa 0.15 μg/mL, respectively[3].
In Vivo	TdR-3H incorporation is significantly inhibited when the animals are exposed to 5-Azacitidine (100 mg/kg, i.p.) for 2 hr or longer[3].
Kinase Assay	A crude cell-free extract is isolated from LI 210 cells in culture by suspension of the cells in a given volume of 0.05mol/LTris-HCl buffer, pH 7.4, and sonic extraction with a Biosonik at 70% maximal output for 30 sec. The supernatant is collected after centrifugation at 105,000 × g for 60 min (4°C) in a Model L Spinco ultracentrifuge. The final protein concentration of the cell-free extracts is approximately 3 mg/mL. The extracts are used as the source of enzymes. Ribonucleotide reductase activity is measured. A unit of enzyme is defined as the amount that catalyzed dCMP synthesis at a rate of 1 mμmole/hr. The assay systems for the measurement of pyrimidine nucleoside (CR) and deoxynucleoside (TdR, CdR) kinases are essentially those described by Chu and Fischer. However, reactions are terminated by heating for 2 min in a boiling water bath, and the phosphorylated derivatives are isolated according to the method of Bach. Fifty-jul aliquots are applied to 1-inch discs of diethylaminoethyl paper, which are then placed in counting vials and eluted with 0.5 mL of 0.5 mol/LPCA. After 1 hr, 12 mL of Diotol are added, and the radioactivity is determined.
Cell Assay	Twenty mL of cells (circa 1×104 cells/mL) are pipetted into sterilized culture tubes with screw caps and incubated at 37°C overnight. The experiment is initiated by the addition of 1 mL of 5-Azacytidine (5-azaCR) or medium for a given period (from 0 to 240 min) prior to the addition of 1 mL of metabolite (or medium). Cell growth is determined twice a day for 3 days by means of a Model A Coulter counter. To determine IDSO and ID90 values, 5 mL of L1210 cells (5×103 cells/mL) are incubated with the drug at 37°C for 3 days, and cell growth is determined.
Animal Admin	For the in vivo experiments, leukemic mice (bearing circa 1×103 cells/animal) are given injections i.p. with 0.2 mL of 5-Azacytidine (5-azaCR) of a given concentration. Two hr later, the reaction is started by injecting 0.5 mL of labeled metabolite (TdR-3H or UR-3H, 10 /μCi/12.5 μg). After 1 hr, animals (3 mice/group) are killed by cervical fracture, and the ascites are treated with heparin, collected, pooled, and then centrifuged immediately in a Sorvall refrigerated centrifuge Model R2C-B at 800×g for 10 min (4°C).
References	[1]. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002 Aug 12;21(35):5483-95. [2]. Creusot F, et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidineand 5-aza-2'-deoxycytidine. J Biol Chem. 1982 Feb 25;257(4):2041-8. [3]. Li LH,et al. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970 Nov;30(11):2760-9.

Density	2.1±0.1 g/cm3
Boiling Point	534.5±60.0 °C at 760 mmHg
Melting Point	226-232 °C (dec.)(lit.)
Molecular Formula	C8H12N4O5
Molecular Weight	244.205
Flash Point	277.0±32.9 °C
Exact Mass	244.080765
PSA	143.72000
LogP	-1.99
Vapour Pressure	0.0±3.2 mmHg at 25°C
Index of Refraction	1.823
Water Solubility	0.5-1.0 g/100 mL at 21 ºC

Azacitidine (5-Azacytidine) MSDS(Chinese)

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XZ3017500

CHEMICAL NAME :
1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-

CAS REGISTRY NUMBER :
320-67-2

LAST UPDATED :
199801

DATA ITEMS CITED :
87

MOLECULAR FORMULA :
C8-H12-N4-O5

MOLECULAR WEIGHT :
244.24

WISWESSER LINE NOTATION :
T6NVN ENJ DZ A- BT5OTJ CQ DQ E1Q

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
Rinsed with water

ROUTE OF EXPOSURE :
Administration onto the skin

SPECIES OBSERVED :
Rodent - rabbit

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
6 mg/kg/10D-I

TOXIC EFFECTS :
Blood - leukopenia Blood - agranulocytosis

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
500 ug/kg

TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
572 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
68 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
229 mg/kg

TOXIC EFFECTS :
Behavioral - ataxia Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
7200 ug/kg

TOXIC EFFECTS :
Blood - other changes

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Bird - quail

DOSE/DURATION :
>100 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Bird - wild bird species

DOSE/DURATION :
100 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
32500 ug/kg/5D-I

TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - muscle contraction or spasticity Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Primate - monkey

DOSE/DURATION :
30800 ug/kg/14D-I

TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases Related to Chronic Data - death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - hamster

DOSE/DURATION :
180 mg/kg/9W-I

TOXIC EFFECTS :
Blood - leukopenia Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
190 mg/kg/38W-I

TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Lungs, Thorax, or Respiration - tumors Reproductive - Tumorigenic effects - testicular tumors

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
100 mg/kg/50W-I

TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - lymphoma, including Hodgkin's disease Skin and Appendages - tumors

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
1 mg/kg female 16 day(s) after conception

TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - transplacental tumorigenesis Blood - lymphoma, including Hodgkin's disease

TYPE OF TEST :
TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
284 mg/kg/43W-I

TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Blood - lymphoma, including Hodgkin's disease

TYPE OF TEST :
TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
100 mg/kg/50W-I

TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors

TYPE OF TEST :
TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
90 mg/kg/8W-I

TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Lungs, Thorax, or Respiration - tumors

TYPE OF TEST :
TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
1 mg/kg female 12 day(s) after conception

TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - lymphoma, including Hodgkin's disease Reproductive - Tumorigenic effects - transplacental tumorigenesis

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
1 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
600 ug/kg

SEX/DURATION :
female 13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
4 mg/kg

SEX/DURATION :
female 17 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
450 ug/kg

SEX/DURATION :
female 13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
5 mg/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
500 ug/kg

SEX/DURATION :
female 7 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
1 mg/kg

SEX/DURATION :
female 7 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
2 mg/kg

SEX/DURATION :
female 10 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
2 mg/kg

SEX/DURATION :
female 11 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Parenteral

DOSE :
500 ug/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Parenteral

DOSE :
100 ug/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - physical

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Parenteral

DOSE :
500 ug/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
500 ug/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Unreported

DOSE :
4 mg/kg

SEX/DURATION :
female 15 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

TYPE OF TEST :
Specific locus test

TYPE OF TEST :
Gene conversion and mitotic recombination

TYPE OF TEST :
Sex chromosome loss and nondisjunction

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
Mutation test systems - not otherwise specified

TYPE OF TEST :
Micronucleus test

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
DNA inhibition

TYPE OF TEST :
Mutation test systems - not otherwise specified

TYPE OF TEST :
Mutation test systems - not otherwise specified

TYPE OF TEST :
Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :
Cytogenetic analysis

TEST SYSTEM :
Mammal - species unspecified Lymphocyte

DOSE/DURATION :
400 nmol/L

REFERENCE :
CGCGBR Cytogenetics and Cell Genetics. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.12- 1973- Volume(issue)/page/year: 41,71,1986 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,37,1981 IARC Cancer Review:Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,47,1990 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,37,1981 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,47,1990 IARC Cancer Review:Group 2A IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,47,1990 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5101 No. of Facilities: 88 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 1069 (estimated) No. of Female Employees: 698 (estimated)

Symbol	GHS07, GHS08
Signal Word	Danger
Hazard Statements	H302-H350
Precautionary Statements	P201-P308 + P313
Personal Protective Equipment	Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes	T:Toxic
Risk Phrases	R45;R46;R22
Safety Phrases	S53-S22-S36/37/39-S45
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	XZ3017500
HS Code	2934999090

b-D-Ribofuranos...

CAS#:6974-32-9

N-(Trimethylsil...

CAS#:52523-35-0

~71%

Azacitidine (5-...

CAS#:320-67-2

Literature: ScinoPharm Taiwan Ltd. Patent: US2010/36112 A1, 2010 ; Location in patent: Page/Page column 7 ;

Beta-D-Ribofura...

CAS#:13035-61-5

~40%

Azacitidine (5-...

CAS#:320-67-2

Literature: Ionescu, Dumitru; Blumbergs, Peter Patent: US2004/186283 A1, 2004 ; Location in patent: Page 8 ;

2',3',5'-triace...

CAS#:10302-78-0

~75%

Azacitidine (5-...

CAS#:320-67-2

Literature: SICOR INC.; BIGATTI, Ettore; LUX, Giovanna; PAIOCCHI, Maurizio; GIOLITO, Andrea; TOSI, Simone Patent: WO2010/17374 A1, 2010 ; Location in patent: Page/Page column 18 ;

Precursor 9	Previous 1/3 Next
CAS#:6974-32-9 b-D-Ribofuranos... CAS#:52523-35-0 N-(Trimethylsil... CAS#:13035-61-5 Beta-D-Ribofura... CAS#:10302-78-0 2',3',5'-triace...
DownStream 1
CAS#:65370-90-3 4-amino-1-[4-(h...

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Company Profile

Our company is a high-tech enterprise specializing in chemical raw materials such as electronic materials, optoelectronic materials, semiconductor materials, UV monomers, silane catalysts, cosmetic raw materials, etc. The company integrates research and development, production, customized synthesis, and sales, and is committed to providing customers with high-quality chemical product solutions.

Our Company

Our Advantage

Rich experience

Our products have been exported to many countries, including Germany, Spain, the United Kingdom, the United States, Australia, the Middle East, Asia, and more. We have received highly positive feedback from our clients and have established long-term friendly cooperative relationships with them.

Excellent quality, purity, and competitive price

Excellent quality is one of the cornerstones of our success. We welcome ordering samples for quality testing.